0.24HKD
360.23 MHKD
1.27 BHKD
593.50 M
About DAWNRAYS PHARMACEUTICAL HLDGS
Sector
CEO
Wei Xian Wu
Headquarters
Hong Kong
Website
Founded
1995
ISIN
KYG2687M1006
FIGI
BBG000FMB261
Dawnrays Pharmaceutical Holdings Ltd. operates as an investment holding company, which engages in the development, manufacturing and selling of cephalosporin antibiotics, and various system specific medicines. It operates through the following business segments: Intermediates & Bulk Medicines, and Finished Drugs. The Intermediates & Bulk Medicines segment engages in the manufacturing and selling of intermediates and bulk medicines. The Finished Drugs segment engages in the manufacturing and selling of antibiotics finished drugs and non-antibiotics finished drugs. The company was founded on December 8, 1995 and is headquartered in Hong Kong.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of 2348 is 1.16 HKD — it has decreased by 0.85% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on HKEX exchange DAWNRAYS PHARMACEUTICAL HLDGS stocks are traded under the ticker 2348.
DAWNRAYS PHARMACEUTICAL HLDGS is going to release the next earnings report on Aug 23, 2024. Keep track of upcoming events with our Earnings Calendar.
2348 stock is 1.74% volatile and has beta coefficient of 0.15. Check out the list of the most volatile stocks — is DAWNRAYS PHARMACEUTICAL HLDGS there?
Yes, you can track DAWNRAYS PHARMACEUTICAL HLDGS financials in yearly and quarterly reports right on TradingView.
2348 stock has fallen by 4.92% compared to the previous week, the month change is a 12.78% fall, over the last year DAWNRAYS PHARMACEUTICAL HLDGS has showed a 12.12% decrease.
2348 net income for the last quarter is 75.69 M HKD, while the quarter before that showed 289.46 M HKD of net income which accounts for −73.85% change. Track more DAWNRAYS PHARMACEUTICAL HLDGS financial stats to get the full picture.
Today DAWNRAYS PHARMACEUTICAL HLDGS has the market capitalization of 1.76 B, it has increased by 0.85% over the last week.
DAWNRAYS PHARMACEUTICAL HLDGS dividend yield was 7.62% in 2023, and payout ratio reached 33.31%. The year before the numbers were 6.62% and 31.67% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
Like other stocks, 2348 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade DAWNRAYS PHARMACEUTICAL HLDGS stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So DAWNRAYS PHARMACEUTICAL HLDGS technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating DAWNRAYS PHARMACEUTICAL HLDGS stock shows the sell signal. See more of DAWNRAYS PHARMACEUTICAL HLDGS technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. DAWNRAYS PHARMACEUTICAL HLDGS EBITDA is 388.70 M HKD, and current EBITDA margin is 30.20%. See more stats in DAWNRAYS PHARMACEUTICAL HLDGS financial statements.